Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALKS

ALKS - Alkermes PLC Stock Price, Fair Value and News

$27.77+0.13 (+0.47%)
Market Closed

51/100

ALKS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

51/100

ALKS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALKS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALKS Price Action

Last 7 days

-3%

Last 30 days

-20.4%

Last 90 days

-2.6%

Trailing 12 Months

-17.4%

ALKS RSI Chart

ALKS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALKS Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

19.15

Price/Sales (Trailing)

3.14

EV/EBITDA

13.31

Price/Free Cashflow

9.63

ALKS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

-10.57%

Rev. Growth (Qtr)

-2.45%

ALKS Earnings

Earnings (TTM)

241.7M

Earnings Growth (Yr)

-66.32%

Earnings Growth (Qtr)

-40.38%

ALKS Profitability

EBT Margin

19.75%

Return on Equity

13.28%

Return on Assets

9.72%

Free Cashflow Yield

10.38%

ALKS Investor Care

Shares Dilution (1Y)

2.48%

Diluted EPS (TTM)

1.43

ALKS Alerts

  • 3 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.5B1.5B1.5B1.5B
20241.7B1.5B1.5B1.6B
20231.1B1.5B1.6B1.7B
20221.2B1.2B1.1B1.1B
20211.0B1.1B1.1B1.2B
20201.2B1.2B1.2B1.0B
20191.1B1.1B1.1B1.2B
2018936.7M1.0B1.1B1.1B
2017780.7M804.4M841.5M903.4M
2016623.9M667.7M695.3M745.7M
2015649.8M647.7M640.4M628.3M
2014563.1M577.9M598.1M618.8M
2013575.5M561.9M577.8M596.3M
2012390.0M480.3M532.3M542.6M
2011186.6M219.3M242.1M331.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Alkermes PLC

ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEalkermes.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES2280

Alkermes PLC Frequently Asked Questions

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Alkermes PLC is 4.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ALKS's PE ratio (Price to Earnings) is 19.15 and Price to Sales (PS) ratio is 3.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Alkermes PLC has provided -0.009 (multiply by 100 for percentage) rate of return.